Our dedicated staff possess the skills needed to perform research efficiently and produce effective outcomes. CRI is a highly proficient organization that accommodates an ever-changing medical culture and works extensively with most major pharmaceutical companies, the NIH, as well as CROs. Our organization has the capability to perform all types of clinical trials related to psychiatry and neurology.

We are committed to helping find safer and more effective treatments to Central Nervous System Disorders. Our experienced clinical research associates and project managers have excellent credentials, with over 96 years of experience, and enable the company to meet critical project deadlines. Our organization helps sponsors successfully undertake complex clinical trials by providing the highest quality services and timely enrollment. In addition, we conduct these investigations in a superior and efficient manner.

CRI Worldwide has over 25 years of experience. We provide a broad range of services to meet the specific requirements of clinical development programs according to the standards of Good Clinical Practice (GCP) and ICH guidelines. Our areas of expertise include inpatient and outpatient clinical trials ranging from Phase I to IV. Many of our studies have been published and recognized worldwide (click here for our publications). CRI's Phase I through Phase IV clinical trial experience focuses on Pediatrics, Adolescents & Adults in the following areas:

• ADHD
• Alzheimer’s Disease
• Atypical Depression
• Bioequivalence / Bioavailability
• Cardiac Safety and QTc
• Dose Ranging and Maximum Tolerability
• Drug Interaction
• Drug Metabolism
• General Anxiety Disorder (GAD)
• Major Depressive Disorder (MDD)
• Manic Depression
• Mild Cognitive Impairment (MCI)
• Obsessive Compulsive Disorder (OCD)
• Panic Disorder
• Pharmacokinetics (PK)
• Premenstrual Dysphonic Disorder
• Relapse Depression
• Safety and Efficacy Testing
• Schizo-Affective
• Schizophrenia Sleep Disorders
• Social Anxiety Disorder
• Structure-Activity Relationships
• Surrogate Marker Mechanism of Action Vascular Dementia
• Treatment Resistant Depression
• Vascular Dementia

Our inpatient research facilities are located within fully licensed and accredited medical hospitals. Our Willingboro division is located in the Lourdes Medical Center of Burlington County and our Kirkbride Division is located in The Kirkbride Center in West Philadelphia.

Our facilities in Clementon New Jersey and Northeast Philadelphia work with members of the community in conducting our outpatient research

CRI Clementon is an outpatient facility located in Southern New just 20 miles from Philadelphia. It is approximately 7,000 square feet and houses a modern equipped clinical research facility capable of performing Phase I-IV clinical trials.

CRI Lourdes Hospital Division is located at the Lourdes Medical Center in Willingboro, N.J. within 20 minutes from the metropolitan Philadelphia area. The 22 bed inpatient facility is equipped to perform Phase I trials and is located within the Lourdes Hospital facility.

CRI Willingboro is an outpatient facility located adjacent to Lourdes Hospital. It is a 2,000 square foot facility equipped with the most modern equipment and staffed with CRI trained personnel who are qualified to conduct Phase I-IV trials.

CRI at Kirkbride Center is located within the Kirkbride Center, an acute care psychiatric hospital located at 111 49th Street in west Philadelphia. This facility is equipped and staffed for Phase II-IV clinical trials and conducts inpatient and outpatient clinical trials.

The inpatient team is headed by Steven Glass, MD, our Psychiatric Medical Director. Treatment of patients participating in research studies is assigned to multi-disciplinary teams, including psychiatrists, psychologists, registered nurses, clinical nurse specialists and, of course, dedicated Clinical Research Coordinators (CRC’s).

Through our exclusive partnership with Lourdes Health System in Burlington County, CRI Worldwide conducts a full complement of inpatient trials (Phases I, II, III). Working with the largest private psychiatric hospitals in the region, we offer the most advanced behavioral health diagnostic and treatment services for subjects seeking inpatient trails. We maintain a full-time presence as the research arm of these hospitals. Working together, CRI and Lourdes hospital diagnose, treat, and conduct inpatient research trials in all forms of behavioral health problems of adolescents, adults and older adults. These disease states include, but are not limited to schizophrenia, psychosis, bipolar disorder, depression, anxiety disorders, eating disorders and chemical dependencies occurring with other behavioral healthcare conditions. Upon discharge from the inpatient facility, a patient may continue in his/her clinical trial at our outpatient location.

CRI works with the world’s leading experts in the study of cognition and the cognitive effects of new and emerging compounds. As a result of our long history of working with disease states, CRI is uniquely capable of recruiting and retaining "stable disease state patients" for participation in clinical trials. More and more, sponsors and partners alike are calling on CRI to conduct "cognitive" trials on patients. CRI’s database of more than 3500 disease state patients allows quick access to reliable study subjects.

In an effort to accurately and efficiently simulate a proper testing environment, CRI has created a dedicated Cognition Center. This 3000 square foot facility is equipped with state of the art equipment and is staffed by expert PhD’s and pyschometricians. Working with sponsors, The Cognition Center can be used to conduct all kinds of cognition tests.

Dr. Howard Hassman, Chief Scientific Officer
Dr. Howard Hassman has a vast knowledge of clinical research with over 21 years of experience in the field. He has teamed with the most respected organizations conducting studies that led to medical and technological breakthroughs. Dr. Hassman began conducting clinical trials in 1982 and is considered an expert in the field of Psychopharmacology. Dr. Hassman received his medical degree from the Philadelphia College of Osteopathic Medicine in 1983. He conducted his rotating internship at the John F. Kennedy Memorial Hospital University of Medicine and Dentistry from 1983 to 1984. From 1981 to 1984, at the University of Pennsylvania, he trained as an investigator with W. George Case, MD, Director of Training in the Conduct of Clinical Research. He also trained for 13 years as an investigator with Karl Rickles, MD, Chairman of the Department of Psychiatry at the University of Pennsylvania. Dr. Hassman worked as an Associate Professor in the Department of Psychiatry at the University of Pennsylvania from 1984 to 1993. From 1990 to 1993, he worked for The Prudential Insurance Company of America as a Medical Director for PruCare Plus of San Diego. He is Board Certified in Family Practice as an Osteopathic Physician and Surgeon in California, Pennsylvania and New Jersey.

From 1984 through 1997, Dr. Hassman worked as a General Practitioner at the Family Practice Associates of San Diego, Inc. Dr. Hassman was also Medical Director of his research facility CMCR, which worked together with Dr. Karl Rickels from the University of Pennsylvania from 1981 to 1994. Dr. Hassman also served as an Associate Professor in the department of Psychiatry at the University of Pennsylvania from 1984 to 1994, while in San Diego. In 1998, he established CRI Worldwide and currently serves as its Chief Scientific Officer. Dr. Hassman’s primary areas of research interest include: Depressive Disorders, Anxiety Disorders, Schizophrenia, Alzheimer’s Disease, Panic Disorder, Pediatric and Adult ADHD and Bipolar Disorder. Currently, he is on the Advisory Board at Eli Lilly & Co. for Atomoxetine in ADD and ADHD for Pediatrics, Adolescents and Adults. He is also a member of the Scientific Advisory Group at Organon, Inc. for The New Treatment Option for the Mature Depressed Patient, and serves on the Advisory Panel for Adult ADHD at Novartis.

Dr. Hassman’s many publications include his book Alternative Treatments for Common Conditions, Copyright © 2000 by Quality Medical Publishing, Inc.; the posters “Mirtazapine vs. Sertraline after SSRI Non-Response” and “Mirtazapine vs. Paroxetine in Elderly Depressed Patients”; articles such as “Antidepressants for the Treatment of Generalized Anxiety Disorder: A Placebo Controlled Comparison of Imipramine, Trazodone and Diazepam”, “Buspirone and Imipramine for Treatment of Major Depression in the Elderly”, “Adinazolam, Diazepam, Imipramine and Placebo in Major Depressive Disorder, A Controlled Study” and “Comparative Study of the Clinical Effectiveness of a Pyrethrin-Based Pediculicide with Combing Versus a Permethrin-Based Pediculide with Combing”; and the clinical abstract “Long-term Efficacy and Safety of Rosuvastatin: Results of a 52-week Comparator-Controlled Trial Versus Pravastatin and Simvastatin” and “Multi-site, open label, observational study of the effectiveness and safety of Remeron â SolTab Ô (mirtazapine orally disintegrating tablets in depressed patients who are at least 50 years of age)”. Dr. Hassman has lectured extensively on these and related topics.

Steven J. Glass, MD, Psychiatric Medical Director–Clementon, NJ
Dr. Steven Glass is highly qualified in the fields of Psychiatry and mental health. He joined CRI Worldwide as the Psychiatric Medical Director. His clinical research experience includes the following areas: Depressive Disorder (pediatric, adult and geriatric), Major Depressive Disorder (adult and geriatric), Atypical Major Depressive Disorder, Bipolar Disorder, Generalized Anxiety Disorder (pediatric, adolescent and adult), Panic Disorder, Schizophrenia, Schizo-Affective Disorder, ADHD (pediatric, adolescent and adult) and Alzheimer’s Disease. Additionally, he has extensive experience in the healthcare industry and academia. He worked as the Medical Director for Inpatient Services at Mercy Fitzgerald Hospital, as President of Rainbow Healthcare Associates, as Medical Staff Director of the Mental Health Unit at Rancocas Hospital, as Chairman of the Department of Psychiatry at Bridgeton Division of the South Jersey Hospital System and as Medical Director of the Mental Health Unit at Underwood Memorial Hospital. Academically, he has held positions as Clinical Assistant Professor of Psychiatry at Robert Wood Johnson School of Medicine of Rutgers University, as Adjunct Clinical Assistant Professor of Psychiatry and Human Behavior at Thomas Jefferson University, as Clinical Assistant Professor of Psychiatry at Temple University School of Medicine and as Education Programs Faculty for the Joint Commission on Accreditation of Healthcare Organizations. He completed a psychiatric residency at Thomas Jefferson University Hospital, where he served as the Chief Resident in Psychiatry. He received an MD from Thomas Jefferson Medical College and a Bachelor’s of Arts in Biology from Swarthmore College. He is licensed to practice in New Jersey and Pennsylvania.

Roberta R. Ball, DO, Psychiatric Medical Director– Philadelphia, PA
Dr. Roberta Ball joined CRI Worldwide in 2003 and serves as the Psychiatric Medical Director of the Philadelphia division. Dr. Ball has an extensive background in academic psychiatry at the University of Medicine and Dentistry School (UMDNJ) of Osteopathic Medicine, where she maintained a clinical practice for more than 15 years. While in clinical practice, Dr. Ball has taught and lectured extensively to both medical students and residents.

Dr. Ball completed her Residency in Psychiatry at Thomas Jefferson University Hospital and joined the Department of Psychiatry at Thomas Jefferson University in the Consultation and Liaison Division. At the University of Medicine and Dentistry School (UMDNJ) of Osteopathic Medicine, Dr. Ball served as Director of Residency Training as well as the Director of Outpatient Services in the Department of Psychiatry.

Dr. Ball’s many publications include: "Dimensions of the Beck Depression Inventory-II in clinically depressed outpatients", Journal of Clinical Psychology; "Screening for Major Depressive Disorders in Medical Inpatients with the Beck Depression Inventory-PC", Behavior Research and Therapy; "Use of the Beck Anxiety and Depression Inventories with Medical Outpatients", Assessment; "Further Evidence for the construct validity of the Beck Depression Inventory-II with Psychiatric Outpatients", Psychological Reports; "Comparison of the Beck Depression Inventories-IA and II in Psychiatric Outpatients", Journal of Personality Assessment; "Chronic Pain", The Jefferson Journal of Psychiatry.

As a Distinguished Fellow of the American Psychiatric Association (APA), Dr. Ball has served as President of her local chapter and has been a representative to the New Jersey Psychiatric Association and is a Fellow of the American Osteopathic College of Neurology. Also, Dr. Ball has served on the American Osteopathic Board of Neurology and Psychiatry and continues to be a Board Examiner. Dr. Ball is currently on the Board of Governors of the American Osteopathic College of Neuropsychiatrists. Dr. Ball is Board Certified in General Psychiatry and has a Certificate of Added Qualification in Geriatric Psychiatry.

David G. Krefetz, DO, MBA, FAPA, FACN, Director of the Pediatric Center for Excellence
Dr. David Krefetz is a Child and Adolescent and General Psychiatrist. He received his medical degree in 1985 from Des Moines University College of Osteopathic Medicine and Surgery in Iowa. He completed his undergraduate education at the University of Pennsylvania in Philadelphia, and graduated in 2002 from the Temple University-Fox School of Business Executive MBA program in Philadelphia. Dr. Krefetz completed his internship at Memorial Hospital in York, PA, and completed his Psychiatry Residency, Child and Adolescent Psychiatry Fellowship at the Medical College of Pennsylvania/Eastern Pennsylvania Psychiatric Institute in Philadelphia. Dr. Krefetz has been Board Certified in Psychiatry and in Child Adolescent Psychiatry by both the American Board of Psychiatry and Neurology, as well as by the American Osteopathic Board of Neurology and Psychiatry. He has also received certification in Administrative Psychiatry by the American Psychiatric Association. Dr. Krefetz is currently the Director of the Pediatric Center for Excellence at CRI Worldwide (CRI), with offices in Clementon, NJ and Philadelphia, PA. Previously, he was full time faculty at the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine (UMDNJ-SOM) where he served as the Director of Education in Psychiatry. Dr. Krefetz remains on the voluntary faculty at UMDNJ. Dr. Krefetz has clinical experience working in a variety of settings including inpatient, outpatient, community and schools. He has a special clinical interest in disruptive behavior, mood, and anxiety disorders in youth, as well as with patients of all ages with HIV illness. He has been the author of research studies on the evaluation of mood disorders in youth, as well as on the evaluation of depression and pain in persons with HIV illness. Currently, he is involved in a wide range of clinical trials as an investigator and/or a sub-investigator.

Dr. Krefetz has been a frequent presenter at both national and regional professional meetings including at the annual meetings of the American Psychiatric Association and of the American Academy of Child and Adolescent Psychiatry. He has also served as Program Director of the Atlantic Regional Osteopathic Convention in 1996. Dr. Krefetz also lectures frequently to the community. Dr. Krefetz is a Distinguished Fellow of the American Psychiatric Association and a Fellow of the American College of the Neuropsychiatrists. He is a member of the Sigma Sigma Phi National Osteopathic Honor Fraternity and the Beta Gamma Sigma National Business Honor Society. He has been a recipient of the Teaching Service Incentive Award at UMDNJ.

Daniel M. Gruener, MD
Daniel Gruener, M.D. completed his psychiatric training at Jefferson Medical College in Philadelphia in 1991 and served as Chief Resident in Psychiatry during his last year of residency. He has received additional training in pain medicine, is certified in psychiatry and pain medicine and has been on the volunteer teaching faculty of Jefferson Medical College since 1992.

Active both academically and clinically, Dr. Gruener has divided his time between the fields of psychiatry and pain medicine. He has been active in clinical and administrative work in psychiatry, and served as President of the Medical Staff of Friends Hospital in Philadelphia for two years and as Medical Director of Inpatient Services for several years. Dr. Gruener was a member of the board of managers at Friends Hospital for four years. He founded the Friends Hospital Chronic Pain Management program and served as its medical director.

In addition to his administrative posts, Dr. Gruener is involved in clinical research, teaching, clinical practice, and writing in the fields of pain management and psychiatry. He has chaired numerous conferences, continuing medical education programs, advisory boards, and similar activities both nationally and internationally, and is a frequent invited lecturer. Active in many causes related to pain medicine, he currently serves as president of the Greater Philadelphia Pain Society, the Mid-Atlantic branch of the American Pain Society, and has edited the society’s publication, Pain Control in the Hospital. Dr. Gruener recently coauthored the textbook Cognitive Therapy with Chronic Pain Patients with Dr. Aaron Beck of the University of Pennsylvania.

Also active in clinical practice, he continues serving a patient population via a group practice in Abington, Pennsylvania, and was named one of the “Top Docs” by Philadelphia Magazine in 2002. His current projects include serving as senior editor on a guide to treating pain in the primary care setting — a joint effort with the American Pain Society. Dr. Gruener recently completed a guide to treating acute pain for Medscape, an Internet-based medical journal, and reviewed a guide book on pain pharmacology which is currently in press. He is president of the Northeast Neuroscience Institute, a medical education company devoted to the advancement of research and education in psychiatry and pain medicine. Dr. Gruener also performs consulting work, and his current activities include editing Emerging Solutions in Pain, a pain management Website for physicians; developing slide kits; and providing conference planning from a content perspective and marketing input from a clinical perspective for several medical education companies and pharmaceutical companies.

Barbara Kelly, PhD, CNS Sub-Investigator
Dr. Barbara Kelly earned her Doctor of Philosophy degree in Clinical Psychology from Walden University. She received a Master of Arts degree in psychology from Marywood College and a Bachelor of Arts degree in psychology from Muhlenberg College. Dr. Kelly is a licensed psychologist in the state of Pennsylvania and New Jersey. She has many years of experience in community mental health and private practice. Dr. Kelly’s professional memberships include the American Psychological Association and the Pennsylvania Society of Behavioral Medicine and Biofeedback. She is an EMDR level two trained clinician and a Fellow of the Biofeedback Certification Institute of America.

Suhas Shanbhag, MD Dr. Suhas Shanbhag is a full time investigator based out of CRI’s New Jersey Hospital Unit. Working hand in hand with CRI's clinical leadership team -- Dr. Howard Hassman, Chief Scientific Officer, and Dr. Steven Glass, Psychiatric Medical Director, Dr. Shanbhag focuses primarily on research conducted in an inpatient setting. Dr. Shanbhag has many years of experience as a principal and sub investigator. Most recently, she served as a PI at ClinSearch, Inc. in Kenilworth, New Jersey. Dr. Shanbhag can be reached at CRI’s Our Lady of Lourdes Division

Total Quality Improvement (TQI)
Quality improvement is an integral aspect of CRI Worldwide's primary objective to “improve the quality of life”. Our Standard Operating Procedures and conduct of clinical trials are evaluated regularly by our Quality Assurance (QA) Coordinators. CRI has a total of 6 QA personnel who work as a team along side our clinical research coordinators. Our QA Coordinators monitor all CRFs within 24 hours; a physician reviews all ECGs within 24 hours and labs within 48 hours; filing of all ECGs and labs, once reviewed by physician, is completed within 72 hours. In addition, record reviews are ongoing. The QA Coordinators implement specific tools to aggregate and analyze all findings. Reports are generated to show trends and to assess the need for process modification.

Since we have certified clinical research coordinators, continuing education is ongoing. CRI provides an accredited, annual, in-house seminar for all our staff members. This seminar and other internal workshops provide information on new developments and / or revisions to FDA, GCP and ICH guidelines.

Terry Smolenski, CCRC, Director of Regulatory Affairs
Terry has 8 years experience as a clinical research coordinator (CRC). She worked as a CRC and has clinical trial experience in the areas of Attention Deficit Hyperactivity Disorder, Geriatric Nursing Home Patients with Major Depression, Posttraumatic Stress Disorder, Placebo-Controlled Study in Elderly Subjects for Prevention of Clinical Influenza during the Flu Season, Patients with Major Depression and many others. As Director of Regulatory Affairs, Terry maintains the clinical standards of the trials, acts as a liaison between coordinators and sponsors, tracks consent documents, updates 1572s and other pertinent regulatory documents and submits information to IRBs for approval.

Institutional Review Board (IRB)
CRI Worldwide utilizes centralized IRBs, including Western, Copernicus, Schulman, Biomedical, Quorum, IMTCI and Chesapeake; we can utilize others when necessary.

Scheduling Department
Two full-time Scheduling Coordinators gather preliminary information from new patients and arrange first appointments with the appropriate coordinator and physician. The Scheduling Team also sends confirmation letters to first-time patients and coordinates the provision of patient transportation when necessary. It is the goal of CRI to answer the initial questions of new patients and to give them an understanding of clinical trials.

Cardiovascular and Phlebotomy Laboratory
Among the standard medical equipment and supplies, the laboratory houses 13 EKG machines, 4 exam areas, a centrifuge, adequate lab kit storage, a –70° C freezer and a –20° C freezer.

Six Sigma
Six Sigma at CRI means a measure of quality that reaches towards near perfection. It is a disciplined data driven approach and methodology for eliminating defects in any process; from manufacturing to transactional and from product to service.

Through statistical representation, Six Sigma describes quantitatively how a process is performing and to achieve the Six Sigma benchmark a process must not produce more than 3.4 defects per million opportunities. Within this context a defect is defined as anything outside of customer specifications. Process improvement and variation reduction are fundamental objectives accomplished through the application of Six Sigma improvement projects. Under the direction of a Six Sigma Master Black Belt, Six Sigma DMAIC (define, measure, analyze, improve, and control) and DMADV (define, measure, analyze, design, and verify) improvement processes are executed by Six Sigma Green Belts and Black Belts.

The Six Sigma DMAIC process is an improvement system for existing processes that are falling below specification and looking for incremental improvement and the DMADV process is an improvement system used to develop new processes or products at Six Sigma quality levels.

Publications

• K. Rickles, J. London, Ira Fox, H. Hassman, Irma Canalis and Ch. Weise, "Adinazolam, Diazepam, Imipramine and Placebo in Major Depressive Disorder: A Controlled Study," European Journal of Pharmacopsychiatry 24 (1991), 127-131.
• Karl Rickles; Robert Downing, PhD; Edward Schweizer, MD; Howard Hassman DO; "Antidepressants for the Treatment of Generalized Anxiety Disorder: A Placebo-Controlled Comparison of Imipramine, Trazodone and Diazepam;" Archives of General Psychiatry 50 (1993), 884-895.
• C.V. Bainbridge, Pharm D; GL Klein, MD; S. I. Neibart, MD; H. Hassman, DO; K. Ellis, DO; D. Manring, MD; R. Goodyear, RNC; J. Newman, MD; S. Micik, MD; F. Hoehler, PhD; kl and P. Walicke, MD; "Comparative Study of the Clinical Effectiveness of a Pyrethrin-Based Pediculicide with Combing Versus a Permethrin-Based Pediculicide with Combing;" Clinical Pediatrics January 1998, 17-22.
• Edward Schweizer, MD; Karl Rickles, MD; Howard Hassman, DO; and Felipe Garcia-España, PhD; "Buspirone and Imipramine for the Treatment of Major Depression in the Elderly;" Journal of Clinical Psychiatry 59 (April 1998), 175-183.
• "A Double-Blind Multi-Centered, Randomized, Active-Controlled, Two-Arm, Parallel-Group Comparative Study of the Efficacy and Safety Oral HMR3647 Versus Oral Clarithromycin in the Treatment of Community Acquired Pneumonia in Adults" for Hoest Marion Roussel, 1999.
• Howard Hassman, Alternative Treatments for Common Conditions, St. Louis: Quality Medical Publishing, Inc., 1999.
• F.G. Hayden, H.A. Hassman, T. Coats, R. Menedez, T. Bock, and the Pleconaril Respiratory Infection Study Group, "Pleconaril Treatment Shortens Duration of Picornavirus Respiratory Illness in Adults," 2000.
• Michael E. Thase, MD; Charlotte Kremer, MD; Heidi E. Rodrigues; J. Amsterdam; J. Apter; M. Bari; Chula Vista; H. Crabbe; S. Eisen; M. Fava; J. Ferguson; H. Hassman; S. James; N. Kalin; C. Meredith; D. Oren; L. Papp; W. Privitera; R. Riesenberg; Trivedi; T. Walsh; and J. Zajecka; "Mirtazapine Versus Sertraline After SSRI Non-Response;" presented at the ECNP meeting in Munch, Germany September 2000.
• Alan F. Schatzberg, MD; Charlotte Kremer, MD; Heidi Rodrigues; M. Bari; B. Baumel; L. Blake; S. Cheren; O. DeBattista; L. Eisner; B. Falk; S. Hand; H. Hassman; J. Heiser; L. Kerby; E. Kramer; C. Nelson; R. Riesenberg; P. Ripley; L. Rone; G. Small; A. Strauss; and K. Weiss; "Mirtazapine Versus Paroxetine in Elderly Depressed Patients;" presented at the ECNP meeting in Munich, Germany September 2000.
• W. V. Brown, B. K. Zedler, H. E. Bays, H. A. Hassman, R. R. Chitra and E. Miller; "Long-Term Efficacy and Safety of Rosuvastatin: Results of a 52-Week Comparator-Controlled Trial Versus Pravastatin and Simvastatin;" American Rosuvastatin Trialists Group submitted to Annual Congress of European Society of Cardiology September 2001.

Locations

Corporate Office
Cognition Center
130 White Horse Pike
Clementon, NJ 08021
Phone: 856-566-9000
Fax: 856-566-9701

24 Hr. Emergency: 1-800-307-0679

Lourdes Hospital Division - In Patient
218A Sunset Road
Willingboro, NJ 08046
Phone: 609-877-3181
Fax: 609-871-0290

24 Hr. Emergency: 1-800-307-0679

Willingboro Division- Outpatient
1113 Hospital Drive
Willingboro, NJ 08046
Phone: 609-877-7935
Fax: 609-871-2399

24 Hr. Emergency: 1-800-307-0679

Kirkbride Division 111 N. 49th St., Suite 119
Philadelphia, PA 19139
Phone: 215-471-6859
24 Hr. Emergency: 1-877-240-2081

Click here for directions

CenterWatch is listing the following trials that are actively recruiting patients at this center.

• A 52-Week, Open-Label Safety Study of XXXXX in Subjects with Generalized Anxiety Disorder
• A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study of the Long-Term Efficacy, Tolerability and Safety of XXXX in the Prevention of Relapse of Major Depression Disorder (MDD) Following Open-Label Treatment of 16-24 Weeks.
• A Blinded-Initiation Study of Medication Satisfaction in Subjects with Schizophrenia Treated with XXXX after Suboptimal Response to Oral Risperidone
• A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of XXXXXX in Patients with Acute Mania Associated with Bipolar I Disorder.
• A Multi-Center Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase IIb Proof of Concept Study with 3 Oral Dose Groups of XXXXXXX during 12 weeks Treatment of Cognitive Deficits in Patients with Schizophrenia.
• A Multicenter, Randomized, Double-blind, Parallel-group, Placebocontrolled Study of the Efficacy and Safety of XXXX Compared with Placebo as an Adjunct to Treatment in Patients with Generalized Anxiety Disorder who Demonstrate Partial or No Response to a Selective Serotonin Reuptake Inhibitor or Serotonin-Norepinephrine Reuptake Inhibitor Alone or in Combination with a Benzodiazepine.
• A Phase 1, 2-Part, randomized, Subject and Investigator Blinded, Placebo-Controlled, Cross-Over Trialto Evaluate the Safety, Tolerabilty, and Pharmocokinetics of XXXXX in Obese, Adult Subjects with Asymptomatic Cholelithiasis.
• A Phase 1b Inpatient, Randomized, Double-Blind, Placebo-Controlled, Crossover Study of the Safety and Efficacy of Two Fixed Doses of XXXXXX in Adjunctive Treatment of Cognitive Deficits in Schizophrenia.
• A Phase 3 Randomized, Placebo-and Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Two Doses of XXXX in Acutely Psychotic Patients with Schizophrenia.
• A Phase 3 Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of Three Doses of XXXX in Acutely Psychotic Patients with Schizophrenia.
• A Phase III Evaluation of the Efficacy and Safety of XXXX as Add-on o Psychostimultant Medication Alone in the Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
• A Randomized, Double-Blind, Placebo-Controlled, 2 Period, Fixed-Sequence Study to Evaluate the Safety, Tolerability, and Pharmacokinectic Profile of Orally Administered XXXXXX in Patients During and Between Their Acute Migraine Attacks.
• A Randomized, Double-Blind, Placebo-Controlled, Risperdone-Referenced, Parallel-Group, Adaptive-Design Study of the Efficacy, Safety, and Tolerability of XXXX in Subjects with Acute Exacerbations of Schizphrenia.
• A Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of XXXX in Subjects with Fibromyalgia
• A Single Dose, Open-Label, Randomized, 2-Period, Parallel Group Study to Asses the Pharmacokinetics, Safety, and Tolerability of XXXX 3-month formulation in Subjects with Schizophrenia.
• A Single-Arm Evaluation of the Safety of XXXX in Subjects with Schizophrenia or Schizoaffective Disorder with Hepatic Disease.
• A Six Week, Double Blind, Multicenter, Placebo Controlled Study Evaluating the Efficacy and Safety of Flexible Doses of Oral XXXX as Add-On, Adjunctive Therapy with Lithium, Valproate or Lamotrigine in Bipolar I Depression
• A Two-Period, Two-Treatment, Open-Label, Two-Way Steady-State Crossover Bioequivalence Study of XXXX under Fasting Conditions in Patients.
• A Two-Week, Double Blind, Placebo Controlled, Randomized, Parallel Group, Efficay and Safety, Out Patient Trial With XXX in Patients With Chronic Primary Insomnia.
• An 8 Week, Double-Blind, Placebo-Controlled, Parallel Group, Fixed Dosage Study to Evaluate the Efficacy and Safety of XXXX as Adjunctive Therapy in Adults with Major Depression Associated with Bipolar I Disorder
• An Ascending, Single-Dose, Single-Blind, Randomized, Placebo-Controlled Study A Phase 1, 2-Part, randomized, Subject and Investigator Blinded, Placebo-Controlled, Cross-Over Trialto Evaluate the Safety, Tolerabilty, and Pharmocokinetics of XXXXX in Obese, Adult Subjects with Asymptomatic Cholelithiasis.
• An Open-Label, Long-Term, Multiple-Dose, Safety and Tolerability, Pharmacokinetic Study of XXXX in the Treatment of Subjects with Schizophrenia.
• An Open-Label, Parallel Group, Dose-Comparison, of XXX and XXX of XXX for Brain Imaging of Amyloid in Healthy Volunteers and Patients with Alzheimer’s Disease.
• Efficacy of XXXX in Combination with Lithium or Valproate in the Long Term Treatment of Mania in Patients with Bipolar I Disorder Partially Nonresponsive to Lithium or Valproate Monotherapy.
• Schizophrenia or Schizoaffective Disorder Clinical Research Study Now Enrolling

For more information, please contact:

Larry Brownstein
Chief Administrative Officer
CRI Worldwide
130 White Horse Pike
Clementon, NJ 08021 USA
Phone: 856-566-9000
Fax: 856-566-4302
E-mail:

If you are interested in contacting this center to discuss placing a clinical trial there, please complete and send the E-mail form below. A representative from the research center will then follow up with you.

Name:
Address:
City:
State:
Zip:
Phone:
Email address:
Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

Last updated on May 1, 2008

PAC>